§ Mr. Michael Morris
To ask the Secretary of State for Health what assessment he has made of the report, "Pharmaceutical Investment in the United Kingdom: the impact of the proposals in the White Paper, Working for Patients", submitted to his Department by the Economist Advisory Group.
§ Mrs. Virginia Bottomley
The report, which was commissioned on behalf of the Pharmaceutical Manufacturers Association of the USA, acknowledges the attractions over the years of the United Kingdom as a place for investment, highlighting research activities in view of this country's strengths in pure science and pharmaceutical innovation. While some concern was reported about future manufacturing investment, there is no reason why these attractions should disappear.